Q-omics provides the consensus-scored FAM99A profile across patient tissues and cancer cell-line models. FAM99A expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, FAM99A is differentially expressed in 5, with the highest sampling consensus in LIHC. Additionally, FAM99A RNA expression shows 6,393 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, LIHC, and STAD as cancer lineages where FAM99A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM99A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM99A survival associations across molecular data types. FAM99A RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM99A RNA expression–survival associations across cancer types. High FAM99A expression shows unfavorable associations in COAD, CESC, LUAD, READ and KIRP, but favorable associations in LIHC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for FAM99A RNA expression.
This table summarizes FAM99A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM99A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM99A shows lower tumor expression in LIHC, CHOL and KICH and higher tumor expression in UCEC and COAD. The LIHC box plot shows higher FAM99A RNA expression in normal versus tumor tissue (log2 FC = −3.899, t-test p < 0.001).
This table shows molecular features associated with FAM99A in patient tissues and cancer cell lines. In patient samples, FAM99A shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
